Novo Nordisk Layoffs: Wegovy Maker Cuts 9,000 Jobs

Novo Nordisk, the maker of Wegovy, is slashing 9,000 jobs—over 11% of its workforce—to save $1.25 billion annually amidst fierce competition with Eli Lilly in the weight loss drug market. The move aims to refocus investments on diabetes and obesity R&D, while Eli Lilly hikes prices for Mounjaro in the UK to potentially lower US costs. Will Novo's restructuring strategy pay off in the long run? Hosted on Acast. See acast.com/privacy for more information.